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Background: 17β-Hydroxysteroid dehydrogenase type-3 (17βHSD-3) deficiency is a rare cause of 46,XY disorders of
sex development. The enzyme converts androstenedione to testosterone, necessary for masculinization of male
genitalia in utero. 17βHSD-3 deficiency is frequently diagnosed late, at puberty, following virilization, with
consequent female-to-male gender reassignment in 39-64%. The decision for sex of rearing is difficult, especially if
diagnosed in early childhood. Consensus guidelines are equivocal or support male gender assignment. Long-term
outcomes data to guide decisions are also lacking; however, in the few cases of early diagnosis and orchiectomy,
female gender retention appears more likely.
We report two patients with 17βHSD-3 deficiency, who presented at unusual ages, in whom female gender was
chosen. We performed a focused literature review and summary of gender outcomes in 17βHSD-3 deficiency
following early orchiectomy.
Cases: Patient A was a phenotypic female who presented at one year of age with bilateral inguinal hernias and
external female genitalia. Testes were identified at surgery. The karyotype was 46,XY. She was initially diagnosed
with complete androgen insensitivity syndrome; however, androgen receptor mutation analysis was negative.
Human chorionic gonadotropin stimulation yielded a low testosterone: androstenedione ratio (0.6, normal >0.8).
Genetic testing demonstrated compound heterozygosity for two known mutations of the HSD17B3 gene. She
underwent bilateral orchiectomy at two years of age.
Patient B was born with female genitalia and virilized at 13 years of age. She did not seek evaluation until 22 years
of age. Her karyotype was 46,XY. She had bilateral inguinal testes and low testosterone: androstenedione ratio (0.3).
HSD17B3 gene sequencing showed her to be a compound heterozygote for two known mutations. She identified
herself as female and underwent bilateral orchiectomy and estrogen replacement therapy.
Conclusions: These two patients highlight the complexities of diagnosis and management in 17βHSD-3 deficiency.
Although existing data are limited, early orchiectomy is likely to result in retention of female gender identity,
avoiding the complications related to virilization in adolescence. As such, it is important to pursue a definitive
diagnosis to guide clinical decisions, and to have the support and long term follow up with an inter-disciplinary
disorders of sex development team.
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Deficiency of the enzyme, 17β-hydroxysteroid dehydro-
genase type 3 (17βHSD-3), is a rare autosomal recessive
disorder of sex development (DSD) in individuals with
46,XY karyotype. 17βHSD-3 is found primarily in the
testes and converts androstenedione to testosterone,
which is necessary for normal masculinization of male
external genitalia in utero. The majority of affected indi-
viduals are born with female or ambiguous external
genitalia [1]. While some individuals may be diagnosed
in infancy or early childhood after evaluation for am-
biguous genitalia or inguinal hernia, many are not diag-
nosed until puberty, when they present with virilization.
Virilization at puberty may be due to residual activity of
17βHSD-3 in the presence of increased androstenedione,
as well as activity of extragonadal 17βHSD isoenzymes
[2]. Gender reassignment from female to male has been
reported in 39-64% in patients who were initially raised
as girls [3].
While decisions regarding gender assignment in pa-
tients with 17βHSD-3 deficiency are difficult at any age,
presentation in early childhood poses additional consid-
erations, including the concern of performing orchiec-
tomy before clear gender identity is evident and/or the
patient is able to assent or consent for surgical proce-
dures. Parents and clinicians must weigh the importance
of deferring surgery until the affected individual is older,
against irreversible surgery at a younger age which may
or may not alter the child’s adjustment or parental dis-
tress [4,5]. However, in patients with 17βHSD-3 defi-
ciency, waiting may not be optimal as a child raised as
female will undergo virilization at puberty if the testes
are retained, which will lead to its own set of medical
and psychosocial implications. In addition, in patients
who elect reassignment to male gender, masculinizing
genitoplasty has less successful outcomes when done in
adulthood [6].
Existing management guidelines are either equivocal
or favor male gender assignment. The 2006 Chicago
consensus statement recommends that the “combination
of a male gender identity in the majority” but the “un-
known” potential for fertility should be considered when
assigning gender in affected infants [7]. The University
of Oklahoma Health Sciences Center’s SUCCEED Clinic
favors male gender assignment in infants with 17βHSD-
3 deficiency as there is a high likelihood of male gender
development. However, due to “an intermediate risk for
germ-cell tumors” and “no reports of fertility thus far”,
they state that “female gender assignment may be appro-
priate in some situations” [8]. Texas Children’s Hospital
Multidisciplinary Gender Medicine Team guidelines rec-
ommend that “when the components of biological sex”
(genomic, anatomic, hormonal, and brain sex) “…do not
strongly align, the goals in such cases should be topreserve the anatomic and physiologic components of a
change in gender identity later in a child’s life” [9]. Fur-
thermore, long term outcomes data are lacking for pa-
tients with 17βHSD-3 deficiency, especially for those
diagnosed at a young age. However, there are a small
number of reported cases who were diagnosed in early
childhood and retained female gender identity following
orchiectomy [10-12].
We report two patients with 17βHSD-3 deficiency
who presented at unusual ages, the first in early child-
hood (who underwent early orchiectomy) and the sec-
ond in early adulthood. These patients highlight the
difficulties encountered with diagnosis and management
in this condition. They also uniquely frame the question
of gender identity at opposite ends of the pediatric age
spectrum, as female gender was maintained in both
cases. We performed a focused review and simple tabu-
lated summary of the existing literature to help guide




Patient A was a Caucasian female who presented to our
center in early childhood. She was born with female ex-
ternal genitalia. When she was 16 months old, she
underwent elective surgery for repair of umbilical and
bilateral inguinal hernias. She was found to have bilateral
inguinal gonads with testicular morphology. Laparo-
scopic evaluation demonstrated bilateral vas deferens
and spermatic vessels; no uterus or ovaries were identi-
fied. Endoscopy of the vagina demonstrated a blind-
ending vagina. Histopathology of the gonadal biopsy
confirmed immature testicular tissue. Chromosome ana-
lysis revealed a 46,XY karyotype in all cells. She was ini-
tially thought to have complete androgen insensitivity
syndrome (CAIS); however, sequencing of the androgen
receptor gene was negative on two separate blood
samples. Subsequent human chorionic gonadotropin
(HCG) stimulation revealed a hormonal profile consist-
ent with 17βHSD-3 deficiency: low stimulated testoster-
one to androstenedione (T/A) ratio of 0.6 (normal >0.8),
and subnormal testosterone response of 2076 pmol/L
(Table 1). Genetic sequencing of the HSD17B3 gene
demonstrated that she was a compound heterozygote for
two known mutations: exon 3 (p.Arg80Trp) and exon 3/
intron 3 junction (c.325+4A->T).
After discussions regarding diagnostic implications
and management options with our inter-disciplinary
DSD team, Patient A’s parents chose to continue to raise
their child as a female, and elected early orchiectomy to
prevent virilization and eliminate any malignancy risk.
Bilateral orchiectomy was performed at age 2.5 years.
Histopathology confirmed normal testes containing
Table 1 Hormonal profiles of patients A and B
Patient A Patient B Norms for
pubertal malesBaseline Post HCG Baseline
Androstenedione (A) (pmol/L) 768 3525 20242 1152 – 6700
Testosterone (T) (pmol/L) 796 2076 5363 12100 – 33560
Dihydrotestosterone (DHT) (pmol/L) 106 303 963 825 – 2235
T/A ratio 0.6 0.3 >0.8
T/DHT ratio 6.8 5.5 <20
Luteinizing hormone (IU/L) 3.8 26.8 3.0 – 10.5
Follicle stimulating hormone (IU/L) 1.7 29.0 4.8 – 20.0
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non-proliferating primitive germ cells. There was no evi-
dence of malignancy. She is currently doing well at age 4
years, and there have been no concerns for gender dys-
phoria to date. She will receive estrogen replacement for
puberty induction and long term hormonal therapy in
the future.
Patient B
Patient B was a Caucasian female who presented to our
center in early adulthood. She was born a phenotypic fe-
male and was raised accordingly. At 13 years of age, she
developed facial and body hair, deepened voice, and
clitoromegaly. She suffered depression and anxiety re-
garding these physical changes, but did not seek medical
evaluation until age 22 years, after she was hospitalized
for depressive symptoms with suicidal ideation and diag-
nosed with bipolar disorder.
Physical examination on presentation was notable for
facial hirsutism, generous bilateral labia majora, and no
palpable inguinal or labial masses. The clitoris was 5 cm
in length, but did not protrude beyond the labia. There
was no vaginal introitus or dimple. The perianal area
was normal. Magnetic resonance imaging of the pelvis
demonstrated utero-vaginal agenesis, seminal vesicles at
the base of the bladder, and bilateral inguinal gonads
(right gonad 2.7 cm × 1.9 cm, left gonad 3.0 cm × 1.8
cm) with testicular morphology. Further workup re-
vealed a 46,XY karyotype and a hormonal profile
consistent with 17βHSD-3 deficiency: low T/A ratio
(0.3, normal >0.8), and low testosterone concentration of
5363 pmol/L (Table 1). Genetic sequencing of the
HSD17B3 gene demonstrated that she was a compound
heterozygote for two known missense mutations: exon 3
(p.Arg80Gln) and exon 9 (p.Val205Glu).
Patient B underwent psychological assessment and
counseling. She identified herself as female, and chose to
proceed with bilateral orchiectomy and estrogen replace-
ment. Histopathology of the gonads confirmed the pres-
ence of testicular tissue with rete testis, epididymis, vas
deferens, Leydig cell hyperplasia, but absent germ cells.There was no evidence of malignancy. Postoperatively,
she was started on transdermal estrogen replacement,
and instructed on techniques for progressive perineal
dilation for vaginal creation. At age 28 years, she is cur-
rently doing well psychologically, and reports comfort-
able and satisfying vaginal intercourse. However, she
continues to have significant hirsutism despite prior or-
chiectomy and good compliance with estrogen therapy.
Discussion
These cases highlight the challenges involved with and
lessons learned from the diagnosis and management of
17βHSD-3 deficiency. Patient A illustrates that 17βHSD-
3 deficiency can be missed if the correct testing is not
performed. Patients with 17βHSD-3 deficiency present
with a primarily female phenotype similar to CAIS. In-
appropriate diagnosis of CAIS may result in the recom-
mendation to retain the gonads for later development of
female secondary sexual characteristics, but will instead
result in unwanted virilization. Therefore, it is important
that 17βHSD-3 deficiency be considered in any 46,XY
phenotypic female and that definitive diagnosis is pur-
sued. This is critical for management, including gender
assignment and the decisions related to orchiectomy.
The complexities of gender decisions are also high-
lighted by our patients’ disparate ages of diagnosis.
Patients who are older, such as Patient B, have the ability
to make their own healthcare decisions, including
consent for surgical procedures. Patient B maintained
female gender, raising the question of whether interven-
tion with early orchiectomy to prevent virilization would
have resulted in a better transition through puberty and
reduced her psychological distress. Patient A presented
an additional dilemma as she was diagnosed in early
childhood, before an age when she could express her
gender identity and assent to orchiectomy. In counseling
Patient A’s parents, we considered the possibility that
raising a child in a gender inconsistent with gonadal and
chromosomal sex could lead to gender dysphoria. Pres-
ence of prenatal androgen production or a Y chromo-
some does not seem to reliably predict development of
Table 2 Gender outcomes in patients with 17βHSD-3 deficiency initially raised female
Female gender maintained Female to male reassignment




Omrani [13] 3 3 ? 0
Ismail [10] 13 5 2 ? 6ǂ 12,14,14,19
Bertelloni [11] 2 1 1 12 0
Mains [14] 1 1 15 0
Lee [15] 4 4 12,14,14 0
Mendonca [12] 10 2 5 15–34 3 15,15, 26
Rosler [16] 9 2 ? 7 10, 12–18
Imperato [17] 1 1 >15
Millan [18] 1 1 ? 0
Lanes [19] 3 3 11–13
Imperato [20] 1 1 14
Akesode [21] 1 1
Total 49 8 19 22
Only subjects followed until at least 12 or more years of age, with explicitly stated gender identity, were reported. Early orchiectomy was defined as orchiectomy
occurring by age 10 years.
*None of the patients who had female to male gender reassignment had had a history of early orchiectomy.
ǂTwo of the patients were assessed to have masculine psychosexual development, but their parents refused gender change.
Table 3 Influence of early orchiectomy on gender













Male 0 22 22
Female 8 19 27
% with development of
male gender identity
0 54 45
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how low levels of androgen produced in individuals with
46,XY disorders of testosterone biosynthesis impact
brain sex development. This unique patient subset may
be similar to CAIS patients before puberty, lacking
effective prenatal androgen exposure on the brain. Bio-
logical factors aside, socialization and learning have been
shown to contribute significantly to gender identity and
role development. The majority of individuals (approxi-
mately 75%) with 46,XY DSD are satisfied with their sex
of rearing as either male or female, as determined by
their parents and physicians [24]. Gender role also ap-
pears to develop in keeping with initial assigned sex as
these individuals proceed through puberty and into
adulthood [25].
Given the uncertainties involved in how best to man-
age a young child with 17βHSD-3 deficiency, all man-
agement options were presented to the parents of
Patient A, including: (1) maintaining female gender with
early orchiectomy, (2) delaying surgery to enable longi-
tudinal gender assessment, with or without delaying
puberty onset with leuprolide therapy, or (3) male gen-
der re-assignment with early or late genital reconstruc-
tion. Patient A was already being raised as a girl, and her
parents decided to proceed with early orchiectomy to
maintain female gender.
In order for Patient A’s family to make an informed
decision, we performed a focused review of the literature
on gender outcomes in 17βHSD-3 deficiency (Table 2).
Only patients initially raised female with follow-up to
age 12 years or older and with documented genderidentity were included. In addition, we assessed and
summarized the influence of early orchiectomy (by age
10 years) on gender (Table 3), as this had not been col-
lectively reported in the past. For the eight patients who
had early orchiectomy, the majority underwent surgery
in early childhood, with a single patient having surgery
at age 10 years, prior to virilization. All eight subjects
retained female gender identity after age 12 years, with
the longest follow-up extending to age 26 years. One
subject was assessed to have androgynous psychosexual
development but did not reassign to male gender [10].
Of the remaining patients who did not undergo early
orchiectomy, diagnosis occurred at or after puberty,
following referral for virilization, lack of breast develop-
ment, or primary amenorrhea. About half reassigned to
male gender during adolescence or early adulthood,
while half remained female, like Patient B. Of the case
reports that described outcomes for those who remained
female, orchiectomy was subsequently performed in ado-
lescence or early adulthood (Table 2). These data suggest
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male gender reassignment in the setting of early child-
hood diagnosis. Early orchiectomy may be justified in
view of retention of female gender identity, but the data
are limited.
We recognize the limitations of presenting two pa-
tients in order to suggest recommendations regarding
orchiectomy and sex of rearing. It is important to note
that male genital reconstruction can be very difficult in
these cases and, despite the degree of virilization seen
with Patient B, the clitoris was quite small. This raises
the concern that even after assignment to a male gender,
there may be the potential for dissatisfaction with the
cosmetic appearance of the genitalia [6]. To date, many
of the outcomes regarding masculinizing surgery are
either short term or retrospective, and may be based on
outdated surgical practices.
More outcomes research is needed to guide gender de-
cisions in patients diagnosed with this condition during
early childhood. For patients raised female who undergo
early orchiectomy, more long term outcomes data re-
garding gender identity is needed, as well as data related
to quality of life, compliance with sex hormone replace-
ment in adolescents and young adults, and sexual func-
tion, in order to better counsel families like those of
Patient A. For patients raised male with retention of tes-
tes, more data regarding outcomes of masculinizing
genitoplasty, sexual function, fertility, and malignancy
risk is needed. Fertility in 17βHSD-3 deficiency does not
appear likely. While there is a single reported case of a
patient (with a history of masculinizing genitoplasty in
adolescence) having fathered a child [6], documented
testicular histology in these patients does not appear to
be consistent with reproductive capacity. Gonadal tissue
removed from younger patients demonstrates germ cells;
however germ cells are absent, as in Patient B, or very
immature at puberty [6,15]. It is unknown whether early
testosterone therapy and orchidopexy would result in a
more favorable outcome. With regards to malignancy,
an intermediate risk (28%) of germ cell malignancy has
been cited in those who did not undergo orchiectomy;
however, this risk is based on only a few patients [7].
Conclusions
Our two patients provide a unique opportunity to learn
from opposite ends of the pediatric age spectrum. They
highlight the complexities of diagnosis and management
of this condition. Our summary of the literature on gen-
der outcomes in 17βHSD-3 deficiency suggests that early
orchiectomy is likely to result in retention of female gen-
der identity. However, the existing data are still very lim-
ited, and there is a need for long term outcomes data in
more patients, which may be best facilitated by national
and international collaborative patient registries, giventhe rarity of this disorder. From a clinical perspective,
pursuing a definitive diagnosis is critical, and patients
and families need long term follow-up and support with
an inter-disciplinary DSD team.
Consent
Written informed consent was obtained from Patient A’s
parents and Patient B for publication of this case report.
Copies of the written consents are available for review
by the Editor-in-Chief of this journal.
Abbreviations
17βHSD-3: 17β-hydroxysteroid dehydrogenase type 3; DSD: Disorder
of sex development; CAIS: Complete androgen insensitivity syndrome;
HCG: Human chorionic gonadotropin; T: Testosterone; A: Androstenedione;
DHT: Dihydrotestosterone.
Competing interests
None of the authors have any competing interests to report.
Authors’ contributions
All authors have made substantive intellectual contributions to this
manuscript. JC and MR were responsible for conceptualizing, designing,
writing and revising the report. JC did the background research. AV, LB, HS,
SA and PC wrote sections of and revised the manuscript critically. All
authors, individually and as a team, were directly involved in the clinical
diagnosis and management of one or both patients. All authors have read
and approved the final manuscript.
Acknowledgements
There are no further acknowledgements needed. None of the authors have
received funding for this work.
Author details
1Division of Endocrinology, Cincinnati Children's Hospital Medical Center,
3333 Burnet Avenue, Cincinnati, Ohio 45229, USA. 2Adolescent Medicine,
New York Medical College, Munger Pavilion, Rm 123, Valhalla, New York
10595, USA. 3Pediatric and Adolescent Gynecology, Cincinnati Children’s
Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio 45229, USA.
4Division of Human Genetics, Cincinnati Children's Hospital Medical Center,
3333 Burnet Avenue, Cincinnati, Ohio 45229, USA. 5Division of Pediatric
Urology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue,
Cincinnati, Ohio 45229, USA. 6Neurology, UC Physicians/ University of
Cincinnati, 222 Piedmont Avenue, Ste. 3200, Cincinnati, Ohio 45219, USA.
Received: 4 June 2013 Accepted: 3 September 2013
Published: 12 September 2013
References
1. Achermann JC, Hughes IA: Disorders of sex development. In Williams
Textbook of Endocrinology. 12th edition. Edited by Melmed S, Polonsky KS,
Larsen PR, Kronenberg HM. Philadelphia: Saunders; 2011:904–905.
2. Rosler A, Belanger A, Labrie F: Mechanisms of androgen production in
male pseudohermaphroditism due to 17 beta-hydroxysteroid
dehydrogenase deficiency. J Clin Endocrinol Metab 1992, 75:773–778.
3. Cohen-Kettenis PT: Gender change in 46, XY persons with 5alpha-
reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3
deficiency. Arch Sex Behav 2005, 34:399–410.
4. Karkazis K, Rossi WC: Ethics for the pediatician: disorders of sex
development: optimizing care. Pediatr Rev 2010, 31:e82–85.
5. Fedele DA, Kirk K, Wolfe-Christensen C, Phillips TM, Mazur T, Mullins LL,
Chernausek SD, Wisniewski AB: Primary caregivers of children affected by
disorders of sex development: mental health and caregiver
characteristics in the context of genital ambiguity and genitoplasty.
Int J Pediatr Endocrinol 2010, 2010:690674.
6. Farkas A, Rosler A: Ten years experience with masculinizing genitoplasty
in male pseudohermaphroditism due to 17 beta-hydroxysteroid
dehydrogenase deficiency. Eur J Pediatr 1993, 152(Suppl 2):S88–90.
Chuang et al. International Journal of Pediatric Endocrinology 2013, 2013:15 Page 6 of 6
http://www.ijpeonline.com/content/2013/1/157. Houk CP, Hughes IA, Ahmed SF, Lee PA: Summary of consensus statement
on intersex disorders and their management. International Intersex
Consensus Conference. Pediatrics 2006, 118:753–757.
8. Palmer BW, Wisniewski AB, Schaeffer TL, Mallappa A, Tryggestad JB, Krishnan
S, Chalmers LJ, Copeland K, Chernausek SD, Reiner WG, Kropp BP: A model
of delivering multi-disciplinary care to people with 46 XY DSD.
J Pediatr Urol 2012, 8:7–16.
9. Douglas G, Axelrad ME, Brandt ML, Crabtree E, Dietrich JE, French S,
Gunn S, Karaviti L, Lopez ME, Macias CG, et al: Consensus in Guidelines
for Evaluation of DSD by the Texas Children's Hospital Multidisciplinary
Gender Medicine Team. Int J Pediatr Endocrinol 2010,
2010:919707.
10. Ismail SI, Mazen IA: A Study of Gender Outcome of Egyptian Patients with
46, XY Disorder of Sex Development. Sex Dev 2010, 4:285–291.
11. Bertelloni S, Balsamo A, Giordani L, Fischetto R, Russo G, Delvecchio M,
Gennari M, Nicoletti A, Maggio MC, Concolino D, et al: 17 beta-Hydroxys-
teroid dehydrogenase-3 deficiency: from pregnancy to adolescence.
J Endocrinol Invest 2009, 32:666–670.
12. Mendonca BB, Inacio M, Arnhold IJP, Costa EMF, Bloise W, Martin RM, Denes
FT, Silva FAQ, Andersson S, Lindqvist A, Wilson JD: Male
pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase
3 deficiency - diagnosis, psychological evaluation, and management.
Medicine 2000, 79:299–309.
13. Omrani MD, Adamovic T, Grandell U, Saleh-Gargari S, Nordenskjold A:
17-beta-hydroxysteroid dehydrogenase type 3 deficiency in three adult
Iranian siblings. Sex Dev 2011, 5:273–276.
14. Mains LM, Vakili B, Lacassie Y, Andersson S, Lindqvist A, Rock JA: 17beta-
hydroxysteroid dehydrogenase 3 deficiency in a male pseudohermaph-
rodite. Fertility and sterility 2008, 89(228):e213–227.
15. Lee YS, Kirk JM, Stanhope RG, Johnston DI, Harland S, Auchus RJ, Andersson
S, Hughes IA: Phenotypic variability in 17beta-hydroxysteroid dehydro-
genase-3 deficiency and diagnostic pitfalls. Clin Endocrinol
(Oxf ) 2007, 67:20–28.
16. Rosler A, Silverstein S, Abeliovich D: A (R80Q) mutation in 17 beta-
hydroxysteroid dehydrogenase type 3 gene among Arabs of Israel is
associated with pseudohermaphroditism in males and normal
asymptomatic females. J Clin Endocrinol Metab 1996, 81:1827–1831.
17. Imperato-McGinley J, Akgun S, Ertel NH, Sayli B, Shackleton C: The
coexistence of male pseudohermaphrodites with 17-ketosteroid
reductase deficiency and 5 alpha-reductase deficiency within a Turkish
kindred. Clin Endocrinol (Oxf ) 1987, 7:135–143.
18. Millan M, Audi L, Martinez-Mora J, Martinez de Osaba MJ, Viguera J,
Esmatjes E, Peig M, Vilardell E: 17-ketosteroid reductase deficiency in an
adult patient without gynaecomastia but with female psychosexual
orientation. Acta Endocrinol (Copenh) 1983, 102:633–640.
19. Lanes R, Brown TR, de Bustos EG, Valverde B, Pieretti RB, Bianco N, Ortega
G, Migeon CJ: Sibship with 17-ketosteroid reductase (17-KSR)
deficiency and hypothyroidism. Lack of linkage of histocompatibility
leucocyte antigen and 17-KSR loci. J Clin Endocrinol Metab 1983,
57:190–196.
20. Imperato-McGinley J, Peterson RE, Stoller R, Goodwin WE: Male
pseudohermaphroditism secondary to 17 beta-hydroxysteroid
dehydrogenase deficiency: gender role change with puberty.
J Clin Endocrinol Metab 1979, 49:391–395.
21. Akesode FA, Meyer WJ, Migeon CJ: Male pseudohermaphroditism with
gynaecomastia due to testicular 17-ketosteroid reductase deficiency.
Clin Endocrinol (Oxf ) 1977, 7:443–452.
22. Mazur T: Gender dysphoria and gender change in androgen insensitivity
or micropenis. Arch Sex Behav 2005, 34:411–421.
23. Dessens AB, Slijper FM, Drop SL: Gender dysphoria and gender change in
chromosomal females with congenital adrenal hyperplasia. Arch Sex
Behav 2005, 34:389–397.
24. Migeon CJ, Wisniewski AB, Gearhart JP, Meyer-Bahlburg HF, Rock JA, Brown
TR, Casella SJ, Maret A, Ngai KM, Money J, Berkovitz GD: Ambiguous
genitalia with perineoscrotal hypospadias in 46, XY individuals: long-term medical, surgical, and psychosexual outcome. Pediatrics 2002,
110:e31.
25. Pappas KB, Wisniewski AB, Migeon CJ: Gender role across development in
adults with 46, XY disorders of sex development including perineoscro-
tal hypospadias and small phallus raised male or female.
J Pediatr Endocrinol Metab 2008, 21:625–630.
doi:10.1186/1687-9856-2013-15
Cite this article as: Chuang et al.: Complexities of gender assignment in
17β-hydroxysteroid dehydrogenase type 3 deficiency: is there a role for
early orchiectomy?. International Journal of Pediatric Endocrinology
2013 2013:15.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
